{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:31:47Z","timestamp":1790811107600,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semnuclmed.2022.12.006","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T07:56:20Z","timestamp":1673337380000},"page":"413-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update"],"prefix":"10.1053","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-1965","authenticated-orcid":false,"given":"Francesco","family":"Cicone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-0686","authenticated-orcid":false,"given":"Giulia","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Lucio","family":"Cascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-9635","authenticated-orcid":false,"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1148\/35.1.51","article-title":"Nuclear physics and therapy: preliminary report on a new method for the treatment of leukemia and polycythemia","volume":"35","author":"Lawrence","year":"1940","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s002590050518","article-title":"Milestones in nuclear medicine","volume":"27","author":"McCready","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0003","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semnuclmed.2005.02.006","article-title":"Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs)","volume":"35","author":"DeNardo","year":"2005","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0004","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1634\/theoncologist.2008-0020","article-title":"Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma","volume":"13","author":"Buchegger","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/172460088700200107","article-title":"Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies","volume":"2","author":"DeNardo","year":"1987","journal-title":"Int J Biol Markers"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0006","first-page":"239","article-title":"Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody","volume":"13","author":"DeNardo","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0007","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma","volume":"16","author":"DeNardo","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0008","first-page":"3330","article-title":"67Copper-2-iminothiolane-6-p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma","volume":"5","author":"O'Donnell","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0009","first-page":"3647","article-title":"A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma","volume":"20","author":"O'Donnell","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10428140310001616935","article-title":"Bischof Delaloye A: The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL)","volume":"44","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0011","first-page":"68","article-title":"Boom-Boom\u201d radioimmunotherapy of lymphomas: Are two magic bullets better than one?","volume":"5","author":"Cicone","year":"2016","journal-title":"Transl Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0012","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.3390\/cancers13215570","article-title":"Radioimmunotherapy in Oncology: Overview of the last decade clinical trials","volume":"13","author":"Rondon","year":"2021","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0013","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.7150\/thno.57177","article-title":"Perspectives on metals-based radioimmunotherapy (RIT): moving forward","volume":"11","author":"White","year":"2021","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0014","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical radioimmunotherapy\u2013the role of radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0015","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Canc Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0016","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I].anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0017","first-page":"21S","article-title":"Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience","volume":"39","author":"Wahl","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0018","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0019","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0020","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0021","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","article-title":"Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation","volume":"110","author":"Morschhauser","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0022","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0023","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hon.968","article-title":"Follicular lymphoma at relapse after rituximab containing regimens: Comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan","volume":"29","author":"Cicone","year":"2011","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0024","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0026","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-022-04781-3","article-title":"90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years","volume":"101","author":"Rieger","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0027","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","article-title":"Long-Term Results of the FOLL05 trial comparing R-CVP Versus R-CHOP Versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma","volume":"36","author":"Luminari","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0028","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","article-title":"Fractionated \u2079\u2070Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria","volume":"32","author":"Illidge","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0029","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0030","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-LineIndolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0031","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3892\/mco.2017.1169","article-title":"Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma","volume":"6","author":"Karmali","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0032","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas","volume":"346","author":"Press","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0033","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2007.06869.x","article-title":"High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory\/resistant B-cell non-Hodgkin lymphomas","volume":"139","author":"Ferrucci","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0034","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2011.07.016","article-title":"Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma","volume":"18","author":"Krishnan","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0036","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2967\/jnumed.110.079897","article-title":"90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy","volume":"51","author":"Minarik","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0037","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.108.057331","article-title":"MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan","volume":"50","author":"Fisher","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0038","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0039","first-page":"53","article-title":"Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma","volume":"23","author":"Assi\u00e9","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0040","first-page":"529","article-title":"Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma","volume":"56","author":"Ferrer","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0041","first-page":"98","article-title":"Quantification of dose nonuniformities by voxel-based dosimetry in patients receiving 90Y-ibritumomab-tiuxetan","volume":"28","author":"Cicone","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0042","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0043","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/sonc.2003.23799","article-title":"The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab","volume":"30","author":"Wahl","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0045","first-page":"109","article-title":"Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma","volume":"30","author":"Seldin","year":"2002","journal-title":"J Nucl Med Technol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0046","first-page":"14","article-title":"Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation","volume":"39","author":"Wahl","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0047","first-page":"457","article-title":"Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients","volume":"44","author":"Koral","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0048","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.semnuclmed.2008.05.008","article-title":"Three-dimensional imaging-based radiobiological dosimetry","volume":"38","author":"Sgouros","year":"2008","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0049","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2967\/jnumed.113.136044","article-title":"Tumor-absorbed dose predicts progression-free survival following (131)I-tositumomab radioimmunotherapy","volume":"55","author":"Dewaraja","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/j.semnuclmed.2021.11.001","article-title":"Dosimetric approaches for radioimmunotherapy of non-hodgkin lymphoma in myeloablative setting","volume":"52","author":"Cicone","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0051","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.1991.9.4.548","article-title":"Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody","volume":"9","author":"Goldenberg","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0052","first-page":"5899","article-title":"Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody","volume":"55","author":"Juweid","year":"1995","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0053","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428190009060322","article-title":"Phase I\/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma","volume":"38","author":"Vose","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0054","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002620050371","article-title":"Advantages of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22","volume":"44","author":"Sharkey","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0055","first-page":"2000","article-title":"Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?","volume":"44","author":"Sharkey","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0056","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I\/II study in non-Hodgkin's lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0057","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2352-3026(16)30168-5","article-title":"Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial","volume":"4","author":"Kraeber-Bodere","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0058","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Lind\u00e9n","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0059","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.137.9.3013","article-title":"A unique antigen on mature B cells defined by a monoclonal antibody","volume":"137","author":"Link","year":"1986","journal-title":"J Immunol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4049\/jimmunol.140.3.905","article-title":"The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein","volume":"140","author":"Schwartz-Albiez","year":"1988","journal-title":"J Immunol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0061","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0062","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumors (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0063","first-page":"85","article-title":"Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma","volume":"33","author":"Dahle","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128816","article-title":"Targeted cancer therapy with a novel anti-CD37 beta-particle emitting radioimmunoconjugate for treatment of non-Hodgkin lymphoma","volume":"10","author":"Repetto-Llamazares","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0065","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ejh.13139","article-title":"Combination of 177Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma","volume":"101","author":"Repetto-Llamazares","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0066","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","article-title":"Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"4","author":"Kolstad","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0067","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2967\/jnumed.116.173922","article-title":"Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan","volume":"58","author":"Blakkisrud","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0068","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnumed.116.180471","article-title":"Red marrow-absorbed dose for non-Hodgkin lymphoma patients treated with 177Lu-lilotomab satetraxetan, a novel anti-CD37 antibody-radionuclide conjugate","volume":"58","author":"Blakkisrud","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0069","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.117.195347","article-title":"Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-radionuclide conjugate 177Lu-lilotomab satetraxetan","volume":"59","author":"Blakkisrud","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0070","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00259-018-3964-9","article-title":"Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients","volume":"45","author":"Stokke","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0071","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00259-019-04417-1","article-title":"Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003","volume":"46","author":"Maaland","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230526","article-title":"Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003","volume":"15","author":"Maaland","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0073","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/0284186X.2021.1959635","article-title":"Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable","volume":"60","author":"Blakkisrud","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0074","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-020-05098-x","article-title":"FDG-PET\/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma","volume":"48","author":"L\u00f8ndalen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s11307-022-01731-3","article-title":"FDG-PET\/CT and dosimetric studies of 177Lu-lilotomab satetraxetan in a first-in-human trial for relapsed indolent non-hodgkin lymphoma-are we hitting the target?","volume":"24","author":"L\u00f8ndalen","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0076","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1038\/s41598-022-10139-6","article-title":"89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma","volume":"12","author":"Giesen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0077","first-page":"1490","article-title":"Dosimetric aspects of radiolabeled antibodies for tumor therapy","volume":"27","author":"Humm","year":"1986","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0078","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/ijms17010033","article-title":"Targeted radionuclide therapy of human tumors","volume":"17","author":"Gudkov","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0079","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nucmedbio.2005.12.004","article-title":"Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy","volume":"33","author":"Dahle","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0080","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood-2007-01-066803","article-title":"Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate","volume":"110","author":"Dahle","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0081","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41416-021-01585-6","article-title":"Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma","volume":"125","author":"Durand-Panteix","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0082","doi-asserted-by":"crossref","first-page":"218","DOI":"10.18632\/oncotarget.817","article-title":"Targeted alpha-therapy using Bi-213.anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells","volume":"4","author":"Roscher","year":"2013","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0083","article-title":"Cure of micrometastatic B-cell lymphoma in a scid mouse model using 213Bi Anti-CD20 monoclonal antibody","volume":"122","author":"Havlena","year":"2022","journal-title":"J Nucl Med jnumed"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0084","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2014-11-612770","article-title":"Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model","volume":"125","author":"Green","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0085","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood-2008-11-188896","article-title":"A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody\/radioantibody therapy","volume":"113","author":"Sharkey","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0086","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1158\/1078-0432.CCR-08-0404","article-title":"Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)","volume":"14","author":"Mattes","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0087","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00259-015-3175-6","article-title":"High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab","volume":"43","author":"Weber","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0088","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2014.112110","article-title":"Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: A phase I study in patients with relapsed\/refractory, aggressive non-Hodgkin lymphoma","volume":"99","author":"Witzig","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0089","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1158\/1078-0432.CCR-1004-0009","article-title":"Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods","volume":"11","author":"Sharkey","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0090","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V98.8.2535","article-title":"A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts","volume":"98","author":"Press","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0091","first-page":"437","article-title":"Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts","volume":"44","author":"Subbiah","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0092","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1158\/1078-0432.CCR-07-1223","article-title":"Pretargeted radioimmunotherapy for B-cell lymphomas","volume":"13","author":"Green","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0093","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.leu.2403751","article-title":"Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody","volume":"19","author":"Sharkey","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0094","doi-asserted-by":"crossref","first-page":"5282","DOI":"10.1158\/0008-5472.CAN-08-0037","article-title":"Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody","volume":"68","author":"Sharkey","year":"2008","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0095","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1158\/0008-5472.CAN-16-0571","article-title":"Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B-cell cancers","volume":"76","author":"Green","year":"2016","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0096","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","article-title":"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0097","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2010-05-282327","article-title":"Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease","volume":"16","author":"Park","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0098","first-page":"15","article-title":"Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I\/II study results","volume":"15","author":"Weiden","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0099","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2003-09-3284","article-title":"Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma","volume":"104","author":"Forero","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0100","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2967\/jnumed.108.060426","article-title":"Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas","volume":"50","author":"Olafsen","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0101","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/bc300039r","article-title":"Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model","volume":"23","author":"Natarajan","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0102","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11307-011-0537-8","article-title":"Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL","volume":"14","author":"Natarajan","year":"2012","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0103","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.120.246595","article-title":"Noninvasive evaluation of CD20 expression Using 64Cu-labeled F(ab')2 Fragments of obinutuzumab in lymphoma","volume":"62","author":"Kang","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169828","article-title":"Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"12","author":"Jauw","year":"2017","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0105","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabeled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0106","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00259-011-2008-5","article-title":"Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET","volume":"39","author":"Rizvi","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.006_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.693682","article-title":"CERN-MEDICIS: A review since commissioning in 2017","volume":"8","author":"Duchemin","year":"2021","journal-title":"Front Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822001143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822001143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:59:19Z","timestamp":1762073959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822001143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0001299822001143"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.12.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}